Advancing the World of Health

It allowed us to study gene expression from immune populations of frozen PBMCs from people living with HIV after a nutritional intervention. Fill out the form to receive updates on our latest products and innovations, exclusive promotions, educational tours, and other exciting news. Backed by cutting-edge technology and more than 50 years of flow cytometry expertise Designed and validated for use with cell suspensions, whole blood and tissue pieces.

• These subtle changes would not have been discovered without the use of a powerful, highly sensitive technique such as the BD Rhapsody™ single-cell platform.
• Quality of care, cost efficiency, healthcare worker and patient safety and experience
• In certain places, BD Medical also offers consulting and analytics related services.
• The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard.
• The BD Rhapsody™ single-cell platform has been a key tool for the publication of our clinical research.

Use a variety of training courses for instruments and applications to take full advantage of the capabilities of BD products. Explore our webinar series spanning a broad range of topics and in-depth reviews by senior scientists, professionals and clinicians. Houses many of our pre-designed multicolor flow cytometry panels. Explore a variety of tools for your multicolor flow cytometry, from panel design to selection tools—an array of aids to support your research. These subtle changes would not have betjili online been discovered without the use of a powerful, highly sensitive technique such as the BD Rhapsody™ single-cell platform.

Innovative solutions to power your diagnostics and research

In certain places, BD Medical also offers consulting and analytics related services. In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products.

The name “embecta” represents the company’s commitment to people living with diabetes and its corporate heritage, with the “em-” prefix evoking empathy for people living with diabetes and the empowerment of the new company and the “bect” imbibed from Becton. Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD can help you identify potential “at-risk” patients, empower clinical intervention, and advance health system insights A unique ecosystem to collaborate on flow cytometry panel design, improve cytometer efficiency and manage your laboratory. An interactive tool containing key cell information to help plan your flow cytometry experiments.

BD is a global medical technology company that is advancing the world of health™.

Quality standards, cost controls and efficiency

Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices. BD Medical’s Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.citation needed A comprehensive suite of trusted products, integrated solutions, useful tools and a wealth of information to advance your flow cytometry applications.